Open Beta
TREN
MetriLume
TREN

US marketsINBX

SEC-sourced researchBeta

INBX

Inhibrx Biosciences, Inc.

Company comparison ↗

Data passport

CIK
0002007919
Exchange
Nasdaq
Business activity
— · SIC 2836
Financial inputs
6/6
Filing date
Sep 28, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 200,000.0000 USD; December 2025: 1,300,000.0000 USD1.3M USD0 USD0December 2024December 2025
INBX · Exact amounts and source periods · USD
Period endRevenueFiling date
December 2024200,000.0000Mar 19, 2026
December 20251,300,000.0000Mar 19, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 20251,300,000.0000-140,055,000.0000-129,794,000.0000146,478,000.0000138,485,000.0000Mar 19, 2026
December 2024200,000.00001,687,572,000.0000-194,409,000.0000180,767,000.000047,183,000.0000Mar 19, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenues$1.3MDecember 2025Mar 19, 202610-K
Previous period revenueRevenues$200KDecember 2024Mar 19, 202610-K
Net incomeNetIncomeLoss-$140.06MDecember 2025Mar 19, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$129.79MDecember 2025Mar 19, 202610-K
Total assetsAssets$146.48MDecember 2025Mar 19, 202610-K
Total liabilitiesLiabilities$138.49MDecember 2025Mar 19, 202610-K

New filings

Explore methodology ↗